SCHEMBL20522377

SCHEMBL20522377

Cc1c(C(=O)C(N)CCC(N)=O)c(=O)oc2cc(N)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.46
KDM4E B2RXH2 7/20 0.40
ALDH1A1 P00352 7/20 0.40
HPGD P15428 6/20 0.40
HSD17B10 Q99714 4/20 0.40
GLA P06280 3/20 0.40
GAA P10253 3/20 0.40
CASP1 P29466 3/20 0.40
CASP7 P55210 3/20 0.40
TSHR P16473 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
HSD17B3 P37058 4/20 0.37
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HIF1A Q16665 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ACHE P22303 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3675110 1.00 SRC (0.46) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3675107 0.91 SRC (0.46) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL10783437 0.84 SRC (0.47) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL10779017 0.82 SRC (0.43) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL15101764 0.82 SRC (0.46) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3201776 0.82 SRC (0.46) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7586984 0.82 SRC (0.49) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3275289 0.82 SRC (0.49) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6888225 0.79 SRC (0.53) SRCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL8679670 0.76 SRC (0.53) SRCKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 CN disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
CN-110719910-A Novel inhibitors 前体生物药物股份公司 2020-01-21 CN disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 SRC 1374/4885KDM4E 1773/4885ALDH1A1 1183/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT SRC 3600/4885KDM4E 1119/4885ALDH1A1 1681/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS SRC 3378/4885KDM4E 1078/4885ALDH1A1 1490/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 SRC 1535/4885KDM4E 1254/4885ALDH1A1 1415/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT SRC 3783/4885KDM4E 1160/4885ALDH1A1 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.